FENC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FENC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Fennec Pharmaceuticals's Marketable Securities for the quarter that ended in Sep. 2024 was $0.00 Mil.
The historical data trend for Fennec Pharmaceuticals's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fennec Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Marketable Securities | Get a 7-Day Free Trial | - | - | - | - | - |
Fennec Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Marketable Securities | Get a 7-Day Free Trial | - | - | - | - | - |
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Fennec Pharmaceuticals (NAS:FENC) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosty Raykov | director, officer: Chief Executive Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Chris A Rallis | director | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Adrian Haigh | director | 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27 |
Robert Andrade | officer: Chief Financial Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Marco Maria Brughera | director | VIALE STEFINI 14, MILANO L6 00000 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Shubh Goel | officer: Chief Commercial Officer | 1100 MAXWELL, #522, HOBOKEN NJ 07030 |
Southpoint Capital Advisors Lp | 10 percent owner | 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036 |
Spa Essetifin | 10 percent owner | VIA SUDAFRICA 20, ROME L6 00144 |
Jodi A Cook | director | PO BOX 816, NEWTOWN PA 08540 |
Manchester Management Pr, Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Francesca Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Paolo Cavazza | 10 percent owner | VIA TESSERETE, 10, LUGANO V8 V8 |
Silvia Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Enrico Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By Marketwired • 11-07-2024
By GuruFocus Research • 10-02-2024
By GuruFocus Research • 08-14-2024
By Marketwired • 07-01-2024
By Marketwired • 05-07-2024
By GuruFocus Research • 04-05-2024
By GuruFocus Research • 04-04-2024
By GuruFocus Research • 02-07-2024
By GuruFocus News • 11-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.